VIVE
Viveve Medical, Inc.
Set alert
0.00 USD 0.00 0.00%
0.0001 Day range 0.0001
0.0001 52-week range 0.001
- YTD
- +100.00%
- 1 year
- +100.00%
- Open
- 0.0001
- Prev close
- 0.0002
- Mkt cap
- 2.14K
- Vol
- 2.33K
- Avg vol
- 973
- EPS
- -2.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.06
- Beta
- 0.16
- Short ratio
- 4.15
- Inst. own
- 4.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 4, 2024
- 50-d avg
- 0.33166
- 200-d avg
- 0.60217
- 1y target
- 3.10
Key statistics
- Market cap
- 1.05M
- Enterprise value
- 1.08M
- Trailing P/E
- 0.00
- Forward P/E
- -0.06
- PEG ratio
- 0.00
- Price / sales
- 0.15
- Price / book
- 0.88
- EPS (TTM)
- -2.55
- Beta
- 0.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.83M
- Revenue growth
- 4.20%
- Free cash flow
- -7.58M
- Total cash
- 5.91M
- Total debt
- 6.01M
- Return on equity
- -210.99%
- Shares outstanding
- 10.72M
- Short % of float
- 3.49%
- 50-day average
- 0.33166
- 200-day average
- 0.60217
Analyst view
Consensus: buy
Buy
Price target (mean) 3.10
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 4, 2024
Expected Jan 4, 2024. Consensus EPS estimate -0.62.
Financials — quick view
VIVE Revenue — quarterly 1.68M
VIVE Net income — quarterly -4.98M
VIVE EPS — quarterly -0.59
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 4, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 5, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | -0.59 | — | — |
| Aug 11, 2022 | Jun 1, 2022 | 0.00 | -0.67 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | Ladenburg Thalmann | up | Neutral | Buy |
| Nov 25, 2020 | Ladenburg Thalmann | down | Buy | Neutral |
| Nov 25, 2020 | Maxim Group | down | Buy | Hold |
| Nov 25, 2020 | Mizuho | down | Buy | Underperform |
| Nov 25, 2020 | Mizuho Securities | down | Buy | Underperform |
| Nov 25, 2020 | Stifel Nicolaus | down | Buy | Hold |
About Viveve Medical, Inc.
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- viveve.com
News
- CCC® Build Sheets Delivers Measurable Improvements in Repair Accuracy and Efficiency
- SURMOUNT Advises VIVE Collision on Sale-Leaseback Portfolio Transaction with Four Corners Property Trust
- Mynd Immersive, Select Rehabilitation, HTC VIVE, and AT&T Expand Next Generation of Immersive Therapeutics to More Than 150 U.S. Senior Living Communities
- Why Is Viveve Medical (VIVE) Stock Down 69% Today?
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Thursday
- Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript
- Earnings Scheduled For November 10, 2022
- Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
Your note
Sign in to keep a note on VIVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATKINSON JAMES G | President | Stock Award(Grant) | Jan 28, 2019 | 964,606 |
| BASTA STEVEN L | Director | Stock Award(Grant) | Mar 31, 2019 | 24,199 |
| BUSH LORI H | Director | Stock Award(Grant) | Jul 1, 2018 | 6,530 |
| DURBIN SCOTT C | Chief Executive Officer | Stock Award(Grant) | Jan 28, 2019 | 73,818 |
| GOLDMAN SACHS GROUP INC. | Unknown | Sale | Sep 30, 2019 | 0 |
| JANNEY DANIEL SPENCER | Director | Stock Award(Grant) | Dec 30, 2018 | 1,442,530 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.28% | 244,226 | 23.93K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 0.56% | 60,344 | 5.91K | Dec 30, 2022 |
| State Street Corporation | 0.52% | 55,369 | 5.43K | Dec 30, 2022 |
| Geode Capital Management, LLC | 0.48% | 51,355 | 5.03K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.30% | 32,000 | 3.13K | Dec 30, 2022 |
| Northern Trust Corporation | 0.16% | 17,074 | 1.67K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.06% | 114,011 | 11.17K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.39% | 41,622 | 4.08K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.05% | 5,483 | 537 | Nov 29, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 3,780 | 370 | Nov 29, 2022 |